Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay

Sung Gwe Ahn, Soong June Bae, Changik Yoon, Yoon Jin Cha, Hak Woo Lee, Seung Ah Lee, Jeong Joon

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aim: The 21-gene recurrence score (RS) predicts a clinical benefit of chemotherapy for individuals with ER-positive/HER2-negative breast cancer. Using in vitro chemoresponse assay, we compared the chemosensitivity according to RS in these patients. Method: Among the patients with Oncotype Dx assay, we identified 63 patients who had chemotherapy response assays to doxorubicin based on adenosine triphosphate. The degree of chemosensitivity to doxorubicin was translated into the cell death rate (CDR). The RS was also dichotomized with a cutoff of 26. Results: Of 63 patients, 34 (54%), 17 (27%), and 12 patients (19%) had a low, intermediate, and high RS, respectively. The mean CDR differed significantly according to categorized RS, with 17.3±10.8 in the low RS group vs. 23.6±16.3 in the intermediate RS group vs. 28.8±12.6 in the high RS group (P = 0.024, One-way ANOVA test). The mean CDR was significantly higher in the higher RS (26) group compared with the lower RS (<26) group (P = 0.025, the Student’s t-test), as well as in the high RS (>30) group compared with the low RS (<18) group (P = 0.012, the Student’s t-test). Also, continuous RS and CDR correlated positively (Pearson’s R = 0.337; P = 0.007). High RS demonstrated the odds ratio (OR = 26.33; 95% CI = 1.69–410.0) for predicting tumors with chemosensitivity on the multivariate analysis. Conclusions: The chemosensitivity measured by in vitro chemoresponse assay was different according to the RS. Our findings support that tumors with high RS has the chemosensitivity even though they are luminal/HER2-negative tumors.

Original languageEnglish
Article numbere0187679
JournalPLoS One
Volume12
Issue number11
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

doxorubicin
Cell death
breast neoplasms
Doxorubicin
Assays
Genes
cell death
Breast Neoplasms
Tumors
Recurrence
Chemotherapy
assays
genes
drug therapy
neoplasms
Analysis of variance (ANOVA)
adenosine triphosphate
Cell Death
Adenosine Triphosphate
odds ratio

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Ahn, Sung Gwe ; Bae, Soong June ; Yoon, Changik ; Cha, Yoon Jin ; Lee, Hak Woo ; Lee, Seung Ah ; Joon, Jeong. / Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score : A study based on in vitro chemoresponse assay. In: PLoS One. 2017 ; Vol. 12, No. 11.
@article{e71414b67cb0413fa9a61acb4e01b652,
title = "Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay",
abstract = "Aim: The 21-gene recurrence score (RS) predicts a clinical benefit of chemotherapy for individuals with ER-positive/HER2-negative breast cancer. Using in vitro chemoresponse assay, we compared the chemosensitivity according to RS in these patients. Method: Among the patients with Oncotype Dx assay, we identified 63 patients who had chemotherapy response assays to doxorubicin based on adenosine triphosphate. The degree of chemosensitivity to doxorubicin was translated into the cell death rate (CDR). The RS was also dichotomized with a cutoff of 26. Results: Of 63 patients, 34 (54{\%}), 17 (27{\%}), and 12 patients (19{\%}) had a low, intermediate, and high RS, respectively. The mean CDR differed significantly according to categorized RS, with 17.3±10.8 in the low RS group vs. 23.6±16.3 in the intermediate RS group vs. 28.8±12.6 in the high RS group (P = 0.024, One-way ANOVA test). The mean CDR was significantly higher in the higher RS (26) group compared with the lower RS (<26) group (P = 0.025, the Student’s t-test), as well as in the high RS (>30) group compared with the low RS (<18) group (P = 0.012, the Student’s t-test). Also, continuous RS and CDR correlated positively (Pearson’s R = 0.337; P = 0.007). High RS demonstrated the odds ratio (OR = 26.33; 95{\%} CI = 1.69–410.0) for predicting tumors with chemosensitivity on the multivariate analysis. Conclusions: The chemosensitivity measured by in vitro chemoresponse assay was different according to the RS. Our findings support that tumors with high RS has the chemosensitivity even though they are luminal/HER2-negative tumors.",
author = "Ahn, {Sung Gwe} and Bae, {Soong June} and Changik Yoon and Cha, {Yoon Jin} and Lee, {Hak Woo} and Lee, {Seung Ah} and Jeong Joon",
year = "2017",
month = "11",
day = "1",
doi = "10.1371/journal.pone.0187679",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score : A study based on in vitro chemoresponse assay. / Ahn, Sung Gwe; Bae, Soong June; Yoon, Changik; Cha, Yoon Jin; Lee, Hak Woo; Lee, Seung Ah; Joon, Jeong.

In: PLoS One, Vol. 12, No. 11, e0187679, 01.11.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score

T2 - A study based on in vitro chemoresponse assay

AU - Ahn, Sung Gwe

AU - Bae, Soong June

AU - Yoon, Changik

AU - Cha, Yoon Jin

AU - Lee, Hak Woo

AU - Lee, Seung Ah

AU - Joon, Jeong

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Aim: The 21-gene recurrence score (RS) predicts a clinical benefit of chemotherapy for individuals with ER-positive/HER2-negative breast cancer. Using in vitro chemoresponse assay, we compared the chemosensitivity according to RS in these patients. Method: Among the patients with Oncotype Dx assay, we identified 63 patients who had chemotherapy response assays to doxorubicin based on adenosine triphosphate. The degree of chemosensitivity to doxorubicin was translated into the cell death rate (CDR). The RS was also dichotomized with a cutoff of 26. Results: Of 63 patients, 34 (54%), 17 (27%), and 12 patients (19%) had a low, intermediate, and high RS, respectively. The mean CDR differed significantly according to categorized RS, with 17.3±10.8 in the low RS group vs. 23.6±16.3 in the intermediate RS group vs. 28.8±12.6 in the high RS group (P = 0.024, One-way ANOVA test). The mean CDR was significantly higher in the higher RS (26) group compared with the lower RS (<26) group (P = 0.025, the Student’s t-test), as well as in the high RS (>30) group compared with the low RS (<18) group (P = 0.012, the Student’s t-test). Also, continuous RS and CDR correlated positively (Pearson’s R = 0.337; P = 0.007). High RS demonstrated the odds ratio (OR = 26.33; 95% CI = 1.69–410.0) for predicting tumors with chemosensitivity on the multivariate analysis. Conclusions: The chemosensitivity measured by in vitro chemoresponse assay was different according to the RS. Our findings support that tumors with high RS has the chemosensitivity even though they are luminal/HER2-negative tumors.

AB - Aim: The 21-gene recurrence score (RS) predicts a clinical benefit of chemotherapy for individuals with ER-positive/HER2-negative breast cancer. Using in vitro chemoresponse assay, we compared the chemosensitivity according to RS in these patients. Method: Among the patients with Oncotype Dx assay, we identified 63 patients who had chemotherapy response assays to doxorubicin based on adenosine triphosphate. The degree of chemosensitivity to doxorubicin was translated into the cell death rate (CDR). The RS was also dichotomized with a cutoff of 26. Results: Of 63 patients, 34 (54%), 17 (27%), and 12 patients (19%) had a low, intermediate, and high RS, respectively. The mean CDR differed significantly according to categorized RS, with 17.3±10.8 in the low RS group vs. 23.6±16.3 in the intermediate RS group vs. 28.8±12.6 in the high RS group (P = 0.024, One-way ANOVA test). The mean CDR was significantly higher in the higher RS (26) group compared with the lower RS (<26) group (P = 0.025, the Student’s t-test), as well as in the high RS (>30) group compared with the low RS (<18) group (P = 0.012, the Student’s t-test). Also, continuous RS and CDR correlated positively (Pearson’s R = 0.337; P = 0.007). High RS demonstrated the odds ratio (OR = 26.33; 95% CI = 1.69–410.0) for predicting tumors with chemosensitivity on the multivariate analysis. Conclusions: The chemosensitivity measured by in vitro chemoresponse assay was different according to the RS. Our findings support that tumors with high RS has the chemosensitivity even though they are luminal/HER2-negative tumors.

UR - http://www.scopus.com/inward/record.url?scp=85033451849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033451849&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0187679

DO - 10.1371/journal.pone.0187679

M3 - Article

C2 - 29117208

AN - SCOPUS:85033451849

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e0187679

ER -